Signalling Pathways 2014: Programme

This symposium is designed for medical oncologists, clinical and industry researchers, and young oncologists.

Download the programme now

Symposium objectives

C. Sessa and F. André offer a preview of the 2nd ESMO Signalling Pathways Symposium, a unique opportunity for clinicians to: get a deeper knowledge of the pathway across different diseases; learn the rationale behind targeted drugs and study pre-clinical data already available; review current indications and understand efficacy and side-effects issues.

  • To provide a basic introduction in the preclinical data relevant for the understanding of functional mechanisms in the PI3K/AKT/mTOR pathway
  • To understand basic concepts of translating preclinical observations in the PI3K/AKT/mTOR signalling into cancer clinics
  • To provide an essential update on different aspects important for rational clinical development of the PI3K/AKT/mTOR inhibitors
  • To elaborate from the clinical perspective, in a range of malignant diseases, on recent achievements and the data from currently ongoing clinical trials in targeting all axes of the PI3K/AKT/mTOR pathway

Benefits of attending

  • Lectures are designed to meet high-level educational standards and make an impact on personalised cancer therapy approaches
  • The programme is designed to accelerate the pace of translating novel and emerging cancer treatments to the bedside
  • Maximum interaction between audience and faculty – participation is limited to 200 attendees
  • The size of the event allows for increased networking opportunities
  • Enhanced understanding of this signaling pathway and the complexities related to its targeting in a range of tumour types from top expert faculty